Natixis Purchases 2,751 Shares of Regeneron Pharmaceuticals, Inc. $REGN

08 Dec 2025, 07:02 by Teresa Graham · The Cerbat Gem

Natixis increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 4.0% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 72,180 shares of the biopharmaceutical company’s stock after purchasing an additional 2,751 shares during the period. Natixis owned approximately 0.07% of Regeneron Pharmaceuticals worth $37,894,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Bank of Nova Scotia lifted its holdings in shares of Regeneron Pharmaceuticals by 103.3% in the 2nd quarter. Bank of Nova Scotia now owns 249,278 shares of the biopharmaceutical company’s stock valued at $130,871,000 after acquiring an additional 126,689 shares during the last quarter. Federated Hermes Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 491.2% in the 2nd quarter. Federated Hermes Inc. now owns 245,587 shares of the biopharmaceutical company’s stock worth $128,933,000 after purchasing an additional 204,045 shares during the period. Gabelli Funds LLC raised its holdings in Regeneron Pharmaceuticals by 3.0% during the 2nd quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock valued at $978,000 after buying an additional 55 shares during the period. Tema Etfs LLC lifted its position in Regeneron Pharmaceuticals by 23.4% in the second quarter. Tema Etfs LLC now owns 5,307 shares of the biopharmaceutical company’s stock worth $2,786,000 after buying an additional 1,007 shares during the last quarter. Finally, Marshall Wace LLP boosted its stake in Regeneron Pharmaceuticals by 533.0% during the second quarter. Marshall Wace LLP now owns 239,909 shares of the biopharmaceutical company’s stock worth $125,952,000 after buying an additional 202,009 shares during the period. Institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on REGN. Wells Fargo & Company raised their target price on shares of Regeneron Pharmaceuticals from $615.00 to $700.00 and gave the stock an “equal weight” rating in a report on Thursday, November 20th. Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 14th. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday, December 1st. Canaccord Genuity Group raised their price target on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Morgan Stanley downgraded Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $767.00 price objective on the stock. in a research report on Wednesday, December 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $777.36.

View Our Latest Stock Analysis on Regeneron Pharmaceuticals

Insider Buying and Selling

In related news, VP Jason Pitofsky sold 431 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the transaction, the vice president directly owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. This represents a 9.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the sale, the director directly owned 2,352 shares in the company, valued at approximately $1,538,843.04. This trade represents a 73.43% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $718.36 on Monday. The firm has a market cap of $75.50 billion, a price-to-earnings ratio of 17.20, a PEG ratio of 2.06 and a beta of 0.37. The firm’s fifty day moving average is $650.69 and its two-hundred day moving average is $588.24. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.33 and a current ratio of 4.06. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $800.99.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last issued its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. During the same quarter in the prior year, the business earned $12.46 earnings per share. The company’s revenue was up .9% compared to the same quarter last year. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were issued a $0.88 dividend. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.43%.

Regeneron Pharmaceuticals Company Profile

(Free Report)